EXPLORE!

Teneligliptin: Recent Evidences

  2034 Views

Dr Sujoy Ghosh, Kolkata    18 November 2018

  1. Teneligliptin is a specific DPP-4 inhibitor with dual excretion through hepatic and renal routes.
  2. No dose adjustment is required in hepatic (mild and moderate) or renal dysfunction.
  3. It can be administered irrespective of meals.
  4. Once a day dosing is possible and the drug has low potential for drug-drug interactions.
  5. Treatment with teneligliptin results in significant reduction in HbA1c, FPG and PPG.
  6. It is weight neutral and has low risk of hypoglycemia.
  7. The drug is generally well-tolerated.
  8. Teneligliptin has been found not to cause detectable increase in cardiovascular risk in Japanese and Indian studies. The drug had no clear effect on the occurrence of cardiovascular adverse events, vital signs, ECG or lipid parameters.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.